Caron Jacobson, MD

Expert perspectives on novel approaches to treatment in the relapsed/refractory setting, particularly CAR T-cell therapy, for patients with follicular lymphoma.

Shared insight on the indolent nature of follicular lymphoma and frontline therapy options for this disease.

Closing out their discussion on mantle cell lymphoma, expert panelists share clinical pearls for practicing community physicians.

Panelists use an illustrative clinical case to highlight best practices in sequencing therapy for mantle cell lymphoma and discuss novel combination strategies under investigation.

A brief review of CAR T-cell therapy in relapsed/refractory mantle cell lymphoma as studied in the ZUMA-2 clinical trial of brexucabtagene autoleucel.

Moving to second-line therapy for mantle cell lymphoma, experts discuss available BTK inhibitors, including the novel agent pirtobrutinib.

Shared insight on the optimal selection and use of frontline therapy for patients who present with mantle cell lymphoma.

Expert panelists discuss a number of recent updates in B-cell lymphoma, particularly mantle cell lymphoma, follicular lymphoma and marginal zone lymphoma, that were presented at key conferences in 2021.

Caron Jacobson, MD, discusses the significance of CD19-targeted CAR T-cell therapy in B-cell malignancies.

Caron Jacobson, MD, discusses the approval of brexucabtagene autoleucel in mantle cell lymphoma.

Caron Jacobson, MD, discusses the high-risk patient population within relapsed/refractory indolent non-Hodgkin lymphoma included in the phase 2 ZUMA-5 study.

Caron Jacobson, MD, discusses the interim analysis results of the marginal zone lymphoma cohort in the phase 2 ZUMA-5 study with axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma.

Caron Jacobson, MD, discusses the next steps with axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma.

Caron Jacobson, MD, discusses the design of the phase 2 ZUMA-5 trial in patients with relapsed/refractory indolent non-Hodgkin lymphoma.

Caron Jacobson, MD, discusses the benefit of axicabtagene ciloleucel (axi-cel; Yescarta) in patients with relapsed/refractory follicular lymphoma.

Caron Jacobson, MD, discusses the benefit of axicabtagene ciloleucel (Yescarta) in patients with relapsed/refractory follicular lymphoma.

Caron Jacobson, MD, discusses the safety profile of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma.